<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322552</url>
  </required_header>
  <id_info>
    <org_study_id>HR-APTN-I-007</org_study_id>
    <nct_id>NCT04322552</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects</brief_title>
  <official_title>A Single Arm, Open and Fixed Sequence Study to Investigate the Pharmacokinetic Effects of Apatinib Mesylate on Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apatinib, an oral inhibitor of vascular endothelial growth factor receptor 2#VEGFR-2#,
      Induces Transporter Pgp function in vitro. This study in patients with advanced cancer
      evaluated the effect of Apatinib on Transporter Pgp function by comparing the
      pharmacokinetics of Transporter Pgp-specific probe drugs in the presence and absence of
      Apatinib. The probes used Substrate Digoxin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2020</start_date>
  <completion_date type="Anticipated">September 12, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 12, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics parameter: Cmax of digoxin</measure>
    <time_frame>through study completion, an average of 16 days</time_frame>
    <description>Peak Plasma Concentration (Cmax) of digoxin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameter: AUC of digoxin</measure>
    <time_frame>through study completion, an average of 16 days</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of digoxin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter: Tmax of digoxin</measure>
    <time_frame>through study completion, an average of 16 days</time_frame>
    <description>Time of maximum observed concentration (Tmax) of digoxin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter: T1/2 of digoxin</measure>
    <time_frame>through study completion, an average of 16 days</time_frame>
    <description>Half time (T1/2) of digoxin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters CL/F of digoxin</measure>
    <time_frame>through study completion, an average of 16 days</time_frame>
    <description>Total body clearance for extravascular administration (CL/F) of digoxin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter: Vz/F of digoxin</measure>
    <time_frame>through study completion, an average of 16 days</time_frame>
    <description>Volume of distribution (Vz/F) of digoxin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>through study completion, an average of 16 days</time_frame>
    <description>An adverse event is any untoward medical occurrence in a patient or clinical study participant criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Treament</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In phase A, subjects receiving a single 0.25 mg of digoxin orally and wash-out for 5 days, then apatinib once daily will be conducted on D5 through D16 ； In addition, a single dose of 0.25 mg digoxin (in combination with apatinib) will be orally administered in fasting conditions on D12；</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Mesylate</intervention_name>
    <description>Apatinib at a dosage of will be administered daily from on D5 through D16</description>
    <arm_group_label>Treament</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin tablet</intervention_name>
    <description>Digoxin at a dosage of 0.25mg will be administered at day 1 and day 12</description>
    <arm_group_label>Treament</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Histologically or cytologically confirmed diagnosis of advanced solid tumors. 2. ECOG PS
        score: 0-1; 3. Expected survival ≥ 3 months; 4. Major organs must function normally,
        meeting the following criteria:

          1. Hematology

               1. HB≥100 g/L;

               2. ANC≥1.5×109/L;

               3. PLT≥90×109/L;

          2. Blood biochemistry:

               1. TBIL≤ 1.25×ULN;

               2. ALT and AST≤2.5×ULN;

               3. ALP≤2.5×ULN;

               4. Serum Cr ≤ 1.5 × ULN or endogenous CrCl ≥ 60 mL/min (Cockcroft-Gault formula);

               5. Albumin &gt; 30 g/L;

               6. K+&gt;3.0mmol/L; 5. Able to understand and sign an informed consent form (ICF).

        Exclusion Criteria:

          1. Primary liver cancer; gastric cancer;

          2. Active brain metastasis (medically uncontrolled), carcinomatous meningitis, spinal
             cord compression;

          3. Presence of clinically symptomatic third space fluid;

          4. Uncontrolled hypertension (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg despite optimal
             pharmacological treatment);

          5. Uncontrolled clinically significant heart disease, including but not limited to the
             following: (1) &gt;2 NYHA 2 congestive heart failure; (2) left ventricular ejection
             fraction (LVEF) &lt; 50% (3) heart rate ＜60 (4) Grade II or greater myocardial ischemia
             or myocardial infarction(5) QTc interval ≥ 450 ms in males and ≥ 470 ms in females;

          6. Abnormal coagulation function;

          7. Prior radiotherapy, systemic chemotherapy (&lt; 6 weeks if chemotherapy including
             nitrosoureas or mitomycin), hormone therapy, surgery or target therapy within 4 weeks
             before the study drug administration, or any unresolved AEs &gt; CTC-AE Grade 1;

          8. History of psychotropic substance abuse, alcoholism or drug abuse;

          9. Use of study drugs in other clinical trials within 4 weeks prior to the first dose；

         10. Use of a potent CYP3A4 inhibitor or inducer within 2 weeks prior to the first dose;

         11. Use of any prescription or over-the-counter medication, vitamin products or herbs
             within 2 weeks before taking the investigational drug;

         12. Other factors that may lead to the termination of the participation in the study at
             the discretion of the investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>HuNan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>201203</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LI Yan kun, Ph.D</last_name>
      <phone>13549680713</phone>
      <phone_ext>86</phone_ext>
      <email>Lkunyan@163.com</email>
    </contact>
    <investigator>
      <last_name>LI Yan kun, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wang Hui, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

